简介：backgroundIn-hospital(IH)mortalityforpatientsunderwentpercutaneouscoronaryintervention(PCI)inourcenterfrom1994to2004was1.01%(33/3252).ThePCIvolumeinourstateincreasedquicklyduringthelastfewyears,sodiditinourcenter.MethodsandResultsWeretrospectivelyscreenedatotalof3274caseswhounderwentPCIin2009,amongwhich24(0.73%,P=0.22vs.1994-2004)IHdeathoccurred.Analysisofthese24casesrevealedthatallofthemwerediagnosedasacutecoronarysyndrome(ACS),andhadtheindicationofPCI.Fifteen(63%)carriedachanceof≥10%todieinhospitalaccordingtoGRACEmodel.Significantleft-main(LM)and/ortriple-vesseldisease(TVD)weredefinedin21(88%)cases.SYNTAXscoreswere≥23in15(63%)and≥33in12(50%)cases.CompleterevascularizationwithPCIwasfulfilledinonly5(21%)cases.Myocardialischemiaorheartfunctioncouldn'timprovebyPCIwasthemostfrequentcauseofdeath,whichcontributedtothatof11(46%)cases.Cardiacruptureoccurredinallofthe4patientswithSTelevatedacutemyocardialinfarction(STE-AMI)involvinginferiorventricularwallbut'reserved'anteriorwall,andcontributedmainlytotheirmortality.ConclusionsPost-PCIIHmortalityhasmaintainedlowinourcenter.ItmostlikelyoccursinpatientswithACS.Themajorcauseofdeathisthatmyocardialischemiacouldn'timprovebyPCI,exceptforpatientswithinferiorbutnoanteriormyocardialinfarction,whosufferfromcardiacruptureinstead.

简介：口服抗凝药是心房颤动患者卒中预防的主要手段。与对照组（无治疗）比较，维生素K拮抗剂，如华法林，可减少2／3的心源性卒中的发生，但其抗凝效果难以预测，治疗指数较窄，而且需要常规监测凝血状况，增加了患者和医疗系统的负担。维生素K拮抗剂的这些缺点促使新一代的选择性抑制凝血酶或凝血因子Xa的抗凝药的发展。

简介：IntroductionMyocardialischemiaandanginapectoriscanbecausedbyvariousmechanismssuchascoronaryatherosclerosis,vasospasmorcoronarymicrovasculardysfunction[1].Weherereportacaseofa56-year-oldfemalepatientwithahistoryofpreviouspercutaneouscoronaryinterventions(PCI)whoreportedrepetitiveattacksofrestingangina.Coronaryriskfactorsincludedhypertension,hypercholesterolemia(LDL=97mg/dLonatorvastatin),ex-smoker(ceased2013),andapositivefamilyhistory(fatalmyocardialinfarctioninfatheraged52yearsandbrother59years).